- Home
- ELEV vs RANI Comparison
ELEV vs RANI Comparison
Compare ELEV & RANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELEV
- RANI
- Stock Information
- Founded
- ELEV 2019
- RANI 2012
- Country
- ELEV United States
- RANI United States
- Employees
- ELEV N/A
- RANI N/A
- Industry
- ELEV Biotechnology: Pharmaceutical Preparations
- RANI Medicinal Chemicals and Botanical Products
- Sector
- ELEV Health Care
- RANI Health Care
- Exchange
- ELEV Nasdaq
- RANI Nasdaq
- Market Cap
- ELEV 37.6M
- RANI 41.6M
- IPO Year
- ELEV 2021
- RANI 2021
- Fundamental
- Price
- ELEV $0.66
- RANI $1.48
- Analyst Decision
- ELEV Buy
- RANI Strong Buy
- Analyst Count
- ELEV 6
- RANI 5
- Target Price
- ELEV $7.20
- RANI $11.80
- AVG Volume (30 Days)
- ELEV 4.3M
- RANI 340.5K
- Earning Date
- ELEV 03-05-2025
- RANI 11-14-2024
- Dividend Yield
- ELEV N/A
- RANI N/A
- EPS Growth
- ELEV N/A
- RANI N/A
- EPS
- ELEV N/A
- RANI N/A
- Revenue
- ELEV N/A
- RANI N/A
- Revenue This Year
- ELEV N/A
- RANI N/A
- Revenue Next Year
- ELEV N/A
- RANI N/A
- P/E Ratio
- ELEV N/A
- RANI N/A
- Revenue Growth
- ELEV N/A
- RANI N/A
- 52 Week Low
- ELEV $0.50
- RANI $1.24
- 52 Week High
- ELEV $5.83
- RANI $8.75
- Technical
- Relative Strength Index (RSI)
- ELEV 48.99
- RANI 49.03
- Support Level
- ELEV $0.65
- RANI $1.24
- Resistance Level
- ELEV $0.98
- RANI $1.61
- Average True Range (ATR)
- ELEV 0.12
- RANI 0.10
- MACD
- ELEV -0.01
- RANI 0.04
- Stochastic Oscillator
- ELEV 18.38
- RANI 64.86
About ELEV Elevation Oncology Inc. Common stock
Elevation Oncology Inc is an oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Its lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have the potential to be therapeutically actionable through targeted HER3 inhibition.
About RANI Rani Therapeutics Holdings Inc.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads up to 200 microlitre in liquid form with high bioavailability.